Curanex Pharmaceuticals Inc Common Stock (CURX) vs Skye Bioscience, Inc. (SKYE)

A side-by-side comparison of Curanex Pharmaceuticals Inc Common Stock and Skye Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Curanex Pharmaceuticals Inc Common Stock logo
CURX
Curanex Pharmaceuticals Inc Common Stock
$7M
$4.99HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Skye Bioscience, Inc. logo
SKYE
Skye Bioscience, Inc.
$7M
$1.62HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CURX vs SKYE

growth of $100 · dividends reinvested · last 1y
CURX -93.8% (-93.8%/yr)SKYE -93.9% (-93.9%/yr)CURX compounded faster over this window
050100150200Start $1002026$6$6
CURX SKYE

CURX vs SKYE: by the numbers

  • •SKYE is the larger company ($7M vs $7M market cap).

Metrics side by side

Valuation

MetricCURXSKYE
P/B ratio1.48N/A

Profitability

MetricCURXSKYE
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-218.65%N/A
ROIC-208.39%N/A

Growth (annualized)

MetricCURXSKYE
Total return CAGR (5Y)N/A-60.42%

Go deeper

Full CURX analysisFull SKYE analysisInteractive comparison tool

Dig into the metrics

Curanex Pharmaceuticals Inc Common Stock ROESkye Bioscience ROECuranex Pharmaceuticals Inc Common Stock operating marginSkye Bioscience operating marginCuranex Pharmaceuticals Inc Common Stock revenue growthSkye Bioscience revenue growthCuranex Pharmaceuticals Inc Common Stock free cash flowSkye Bioscience free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.